Zobrazeno 1 - 10
of 159
pro vyhledávání: '"Stephen Opat"'
Autor:
Claire Dendle, Michael Gilbertson, Tim Spelman, Rhonda L. Stuart, Tony M. Korman, Karin Thursky, Stephen Opat, Zoe McQuilten
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-10 (2017)
Abstract To identify risk factors for infection in patients with diffuse large B cell lymphoma (DLBCL) undergoing rituximab, cyclophosphamide, vincristine, adriamycin and prednisolone (R-CHOP) treatment. All patients with DLBCL who received R-CHOP fr
Externí odkaz:
https://doaj.org/article/8a6a1943b81149ab8bde5882ee1cadd6
Publikováno v:
Emerging Infectious Diseases, Vol 21, Iss 9, Pp 1661-1663 (2015)
Two cases of disseminated enteroviral infection occurred in patients who received the CD20 monoclonal antibody obinutuzumab. Clinical features included hepatitis, edema, and a dermatomyositis-like syndrome. These manifestations may be unfamiliar to c
Externí odkaz:
https://doaj.org/article/108dba37573d414286735693d8fb5597
Autor:
Mark P. Hertzberg, Jamie Hirata, Gilles Salles, Laurie H. Sehn, Muhit Ozcan, Grace Ku, Christopher R. Flowers, Alex F. Herrera, Andrew McMillan, Tae Min Kim, Stephen Opat, Lisa Musick, Yi Meng Chang, Violaine Safar, Matthew J. Matasar, Sarit Assouline
Publikováno v:
Blood Advances
Key Points Consistent with previous results, pola + BR has a tolerable safety profile.The survival benefit of pola + BR vs BR persists with longer follow-up; efficacy in the pola + BR extension and randomized arms was similar.
Visual Abstract
Visual Abstract
Publikováno v:
Expert Review of Clinical Pharmacology. 14:1329-1344
Introduction: Bruton's tyrosine kinase (BTK) inhibitors have revolutionized the treatment of B-cell lymphomas. Zanubrutinib was designed to achieve improved therapeutic concentrations and minimize off-target activities putatively accounting, in part,
Autor:
Peter Browett, Kim Linton, Fontanet Bijou, Keshu Zhou, Chris Tankersley, Massimo Cappellini, Melannie Co, Pamela McKay, Eliza A Hawkes, Xiaoyan Ke, Jane Huang, Catherine Thieblemont, Shir-Jing Ho, Robert Marcus, Morton Coleman, Patricia F. Walker, Magdalena Sobieraj-Teague, Alessandra Tedeschi, Sally Mapp, Bei Hu, Dipti Talaulikar, Jie Jin, Stephen Opat, Mingyuan Sun, Craig A. Portell, Pier Luigi Zinzani, Judith Trotman, Xiaotong Li, Kirit M. Ardeshna, Wenxiao Zhou, Henry Chan
Publikováno v:
Opat, S, Tedeschi, A, Linton, K, McKay, P, Hu, B, Chan, H, Jin, J, Sobieraj-Teague, M, Zinzani, P L, Coleman, M, Thieblemont, C, Browett, P, Ke, X, Sun, M, Marcus, R, Portell, C A, Ardeshna, K, Bijou, F, Walker, P, Hawkes, E A, Mapp, S, Ho, S J, Talaulikar, D, Zhou, K S, Co, M, Li, X, Zhou, W, Cappellini, M, Tankersley, C, Huang, J & Trotman, J 2021, ' The MAGNOLIA Trial : Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma ', Clinical Cancer Research, vol. 27, no. 23, pp. 6323-6332 . https://doi.org/10.1158/1078-0432.CCR-21-1704
Purpose: Marginal zone lymphoma (MZL) is an uncommon non–Hodgkin lymphoma with malignant cells that exhibit a consistent dependency on B-cell receptor signaling. We evaluated the efficacy and safety of zanubrutinib, a next-generation selective Brut
Autor:
Elizabeth Coughlin, Stephen Opat, Anouk Dev, Sanjeev Chunilal, Matthew van Dam, Sant-Rayn Pasricha, Michael Gilbertson, Ashwini Bennett, Tishya Indran
Publikováno v:
Internal Medicine Journal. 51:1304-1311
Background Ferric carboxymaltose is increasingly utilised to treat iron deficiency and is usually diluted in saline and administered as an intravenous infusion over 15 minutes. Whilst this is highly convenient compared with older formulations, we hyp
Autor:
Adam J. Olszewski, Damien Kee, Clare L. Scott, Shirley D'Sa, Marie José Kersten, Ibrahim Tohidi-Esfahani, Carl Harrington, Ruth Spearing, Judith Trotman, Peter Liburdi deNardis, Maria Lia Palomba, Stephen Opat, Marita Black, Javier Haurat, Andrew C. Warden, Elena Malunis
Publikováno v:
American journal of hematology, 96(6), E218-E222. Wiley-Liss Inc.
Publikováno v:
Journal of Hematology
Background: Infections are an important cause of morbidity and mortality in T-cell lymphomas. Factors contributing to increased risk of infection include the nature of the underlying disease, as well as treatment-associated immunosuppression. Current
Autor:
Ross Salvaris, Stephen Opat
Publikováno v:
Future Oncology. 17:371-387
In the last decade, the treatment of chronic lymphocytic leukemia (CLL) has shifted away from chemoimmunotherapy toward targeted novel agents such as small molecule inhibitors and antibodies. Here, we give an overview of the pharmacology of venetocla
Autor:
Gandhi Damaj, Deyaa Adib, Sarit Assouline, Michael Dickinson, John Radford, Gilles Salles, Anna Schmitt, Wojciech Jurczak, Jay Yang, Tycel Phillips, Franck Morschhauser, Maciej Kazmierczak, Aristeidis Chaidos, Phillip L. Campbell, Connie Lee Batlevi, Pamela McKay, Hervé Tilly, Stephen Opat, Vincent Ribrag, Jennifer Whalen, Shefali Agarwal
Publikováno v:
Lancet Oncol
Summary Background Activating mutations of EZH2, an epigenetic regulator, are present in approximately 20% of patients with follicular lymphoma. We investigated the activity and safety of tazemetostat, a first-in-class, oral EZH2 inhibitor, in patien